Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

REGN

+ Watchlist+ Portfolio

Regeneron Pharmaceuticals, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$957.76
52-Week Range
$591.52 – $991.73
Market Cap
$97.81B
P/E (TTM)
20.90
EPS (TTM)
45.24
Dividend Yield
0.40%
Advanced Metrics
Price/Book
2.83
PEG Ratio
1.15
Return on Equity
14.95%
Return on Assets
7.59%
Gross Margin
46.73%
Operating Margin
30.38%
Profit Margin
28.51%
Current Ratio
3.35
Debt/Equity
0.08
Total Debt
$2.71B
Free Cash Flow
$2.58B
Revenue Growth
36.30%
Earnings Growth
35.50%
Enterprise Value
$88.29B

Market Snapshot

About

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases. Its marketed products include Eylea for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for skin cancer, and Praluent for cholesterol management, developed using its proprietary VelocImmune antibody technology.